Clinical Trials Browser

NIH × Carcinoma, Non-Small-Cell Lung × Bortezomib × Clear all

NCT00093756 2017-12-07

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

Phase 1/2 Completed

52 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT00362882 2017-12-05

Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer

Phase 2 Completed

81 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT00118144 2014-08-21

Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

Phase 2 Completed

42 enrolled 7 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

NCT00118183 2013-06-04

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant

NCT00075751 2013-02-28

Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00052338 2013-01-23

Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant

NCT00040768 2013-01-16

Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung